期刊论文详细信息
The Journal of Headache and Pain
Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
Dawn C. Buse1  Larry Charleston2  Thomas Brevig3  Roger Cady4  Joe Hirman5  Paul K. Winner6 
[1] Albert Einstein College of Medicine, Bronx, NY, USA;Vector Psychometric Group, LLC, Chapel Hill, NC, USA;Department of Neurology and Ophthalmology, Michigan State University College of Human Medicine, East Lansing, MI, USA;H. Lundbeck A/S, Copenhagen, Denmark;Lundbeck LLC, Deerfield, IL, USA;Pacific Northwest Statistical Consulting, Inc., Woodinville, WA, USA;Palm Beach Headache Center, West Palm Beach, FL, USA;
关键词: Eptinezumab;    Chronic migraine;    Migraine prevention;    Clinical response;   
DOI  :  10.1186/s10194-022-01387-y
来源: Springer
PDF
【 摘 要 】

BackgroundA clinical ability to describe the response trajectory of patients receiving preventive migraine treatment could expedite and improve therapeutic management decisions. This post hoc analysis of the PROMISE-2 study evaluated the consistency and predictive power of Month 1 treatment response on later response in patients with chronic migraine.MethodsPROMISE-2 was a double-blind, placebo-controlled trial that randomized adults with chronic migraine to eptinezumab 100 mg, 300 mg, or placebo administered IV every 12 weeks for up to 24 weeks (2 infusions over 6 study months). Migraine responder rates (MRRs) were calculated from monthly migraine days over 4-week intervals compared with baseline. Patients were grouped by MRR during Month 1 (< 25%, 25–< 50%, 50–< 75%, and ≥ 75%), with the number of subsequent study months (Months 2–6) with ≥50% and ≥ 75% MRR calculated in each subgroup. A similar analysis was conducted using Patient Global Impression of Change (PGIC) rating to define Month 1 subgroups (very much improved, much improved, minimally improved, and no change/worse) and rates of very much improved or much improved PGIC during Months 2–6.ResultsIn the eptinezumab 100 mg, 300 mg, and placebo groups, respectively, 194/356 (54.5%), 212/350 (60.6%), and 132/366 (36.1%) patients were ≥ 50% migraine responders during Month 1. More eptinezumab-treated patients were ≥ 75% migraine responders (100 mg, 110/356 [30.9%]; 300 mg, 129/350 [36.9%]; placebo, 57/366 [15.6%]) and more placebo-treated patients were < 25% migraine responders (eptinezumab 100 mg, 103/356 [28.9%]; 300 mg, 80/350 [22.9%]; placebo, 153/366 [41.8%]). Among patients who achieved ≥75% migraine response in Month 1, more than one-third attained ≥75% migraine response for all 5 subsequent study months and more than two-thirds achieved ≥75% migraine response for ≥3 months. More than two-thirds of those in the very much improved (PGIC) subgroup at Month 1 were much or very much improved for all 5 subsequent months.ConclusionsIn this post hoc analysis of data from PROMISE-2, more eptinezumab-treated than placebo-treated patients were early (Month 1) responders, and most early responders went on to achieve a high level of response for at least half of the 24-week treatment period. Potential for later response in early non-responders was also observed.Trial registrationClinicalTrials.gov identifier: NCT02974153; registered November 23, 2016.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202202186622962ZK.pdf 1951KB PDF download
  文献评价指标  
  下载次数:3次 浏览次数:1次